<div id="readability-page-1"><div>Shares | Ratings | Target prices (HK$)KEYMED BIO-B(02162.HK) +4.400 (+7.593%) Short selling $14.33M; Ratio 17.162% | Overweight | 93.5 -&gt; 97 INNOVENT BIO(01801.HK) +8.650 (+11.556%) Short selling $276.41M; Ratio 19.410% | Overweight | 130 -&gt; 135 LEADS BIOLABS-B(09887.HK) +0.900 (+1.479%) Short selling $549.67K; Ratio 5.201% | Equalweight | 59 -&gt; 62 HUTCHMED(00013.HK) +0.490 (+2.754%) Short selling $5.61M; Ratio 11.319% | Underweight -&gt; Equalweight | 21.4 -&gt; 21.3 REMEGEN(09995.HK) +4.150 (+5.256%) Short selling $16.50M; Ratio 8.949% | Equalweight | 89 -&gt; 98INNOCARE(09969.HK) +0.460 (+4.100%) Short selling $8.23M; Ratio 16.150% | Equalweight -&gt; Overweight | 19.6 -&gt; 17 DUALITYBIO-B(09606.HK) +17.200 (+8.222%) Short selling $8.42M; Ratio 6.536% | Overweight | 493 ABBISKO-B(02256.HK) +0.160 (+1.670%) Short selling $1.47M; Ratio 21.819% | Overweight | 22 ZAI LAB(09688.HK) +0.390 (+2.863%) Short selling $49.75M; Ratio 39.140% | Overweight | 19 VISEN PHARMA-B(02561.HK) -0.180 (-0.803%) Short selling $8.80K; Ratio 1.964% | Overweight | 50 EVEREST MED(01952.HK) +1.400 (+4.871%) Short selling $5.29M; Ratio 9.764% | Equalweight | 40 (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 12:25.)</div></div>

688428

09969

01801

M Stanley has provided ratings and target prices for several China biotech stocks. Keymed Bio-B (Overweight, TP: 97), Innovent Bio (Overweight, TP: 135), and DualityBio-B (Overweight, TP: 493) saw significant price increases. Hutchmed's rating was adjusted from Underweight to Equalweight (TP: 21.3). Other stocks like Remegen and InnoCare received Equalweight ratings with target prices adjusted to 98 and 17, respectively.

AASTOCKS News

InnoCare Pharma

INNOCARE

INNOVENT BIO

REMEGEN

Hutchmed China

RemeGen

Bosera Hang Seng Health Care ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI 300 Health Care ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Universal CNI HK Connect Innovative Drugs Industry ETF

Morgan Stanley

KEYMED BIO-B

LEADS BIOLABS-B

HUTCHMED

DUALITYBIO-B

ABBISKO-B

ZAI LAB

Zai Lab

VISEN PHARMA-B

EVEREST MED

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley Ratings and TPs on China Biotech Stocks